US portfolio and unusual options activity

-->

12th Dec '24 by yiannos1

190 comments 5918 reads

After a couple of weeks of trying to explain the positives of publishing the US portfolio , this has been finally approved.

I will also post any unusual options activity.

Comments about US stocks are very much welcomed. Anything else , including politics , interest rates and stocks NOT listed in the US are not welcomed.

Opinions about whether the US market is underpriced/overpriced are irrelevant.

Experienced investors know very well that this is a growth momentum earnings market and as long as earnings growth is sustained then the market will keep rising.

ANY STOCKS COVERED ARE NOT TO BE REGARDED AS FINANCIAL ADVICE.

DYOR.

Unlock with Email

Unlock with Google

Already have an account?
Login here

About the Author

Yiannos1

Premium Member

190 comments

Rusty2

9th Feb

Even selling £1,000 on many uk small caps moves the price down, shows how thin and sensitive, the market is. Often can't even get a quote, when trying to do a trade, had that even on large caps.

Howard Adams

10th Feb

Hi john2

I have a US sub-portfolio under the theme of telehealth in which I include Hims & Hers Health (NYQ:HIMS) , Teladoc Health (NYQ:TDOC) and Doximity (NYQ:DOCS) .

My broad thesis being that Hims & Hers Health (NYQ:HIMS) is a platform which serves an important need in the US - more affordable, convenient prescriptions and tailored prescriptions.

That both Teladoc Health (NYQ:TDOC) and Doximity (NYQ:DOCS) had been oversold.

Teladoc Health (NYQ:TDOC) of interest because it offers a broad range of healthcare to patients. Spanning health assessments right through to hospital care.

Whilst Doximity (NYQ:DOCS) offered an important service and community to healthcare professionals.

I thought these three offered a complementary investment into the digital (possibly AI driven) US healthcare sector - medicines and prescriptions, full healthcare and support to healthcare professionals.

I still hold the first two but I exited Doximity (NYQ:DOCS) 10/01/25 sadly (will seek to re-enter at some point) as I thought I entered too late on the share price rise mid Nov 24.

Looking at a 6 month chart it seems all three have momentum. Some of you might want to investigate if these suit your investment strategies.

Regards

Howard

john2

10th Feb

Thank you Howard. I made a bigger mistake than selling Doximity (NYQ:DOCS) when I sold Palantir Technologies (NSQ:PLTR) .

Howard Adams

10th Feb

Hi john2

Oh dear I hope you made some profit ... but as I'm sure you are aware I am very bullish on Palantir Technologies (NSQ:PLTR) so I think you ought to keep an eye on it and see if you might re-try it again.

In my view its a stock to cost dollar in/out of with a view to be a long term holder.

But that's just my view. Many hate it and would not go near it at current valuations.

Regards

Howard

john2

10th Feb

I did make a moderate profit. I sold when I saw Gillian Tett describe it as a meme stock in the FT. Did you see the recent FT article describing the comings and goings between Palantir and the Trump administration?

I also have great hopes for their purchase of Anduril, who make more potent weapons than the old-established arms firms at lower cost.

Howard Adams

10th Feb

Hi john2

Glad you made a modest profit.

Yes saw the FT article. FT is a hater of Palantir Technologies (NSQ:PLTR) .

Certainly some will identify Palantir it as a meme stock, as it probably is, over past days as so many buy in after the very positive results the other day.

'I also have great hopes for their purchase of Anduril, who make more potent weapons than the old-established arms firms at lower cost.'

This is not quite correct. Palantir Technologies (NSQ:PLTR) are not buying Anduril. Three of the co-founders of Anduril, alongside Palmer Lucky, are ex-Palantir people. Anduril and Palantir have a strong partnership with each other. Anduril uses AIP as the platform to run their supply chain operations.

I am looking forward to an Anduril IPO at some point.

Regards

Howard

Viz

11th Feb

Thanks for your detailed update again Howard, sorry for the delayed response, I have been busy with other stocks and the occasional bit of work I need to do :D.

Telehealth has gained significant traction in recent years, and I admit, I was later to the party, focusing on space stocks and comms, although driven by increasing healthcare costs I can see the demand for more convenient solutions.

I don’t own Hims & Hers Health (NYQ:HIMS), and have waited (missed my opportunity last year) stands out as a direct-to-consumer platform offering affordable and accessible prescription services. I do wonder though whether competition from giants like Amazon and potential regulatory hurdles pose risks. For now, I’ve held off on investing due to capital constraints (I hold all my shares in ISAs, so lets see what April brings).

Teladoc Health (NYQ:TDOC) , on the other hand, from what I can see provides a more comprehensive healthcare service, spanning from virtual consultations to hospital care. Despite being a leader in telehealth, it has struggled with profitability, although this did not put me off and I took a medium position last year.

Whilst it faces competition from alternative virtual healthcare providers, its expansion into AI-driven tools like the ‘Virtual Sitter’ is an efficient use of tech which I love. I have noted that they have a cost savings program although from memory I think they stood down their 2024 outlook a while ago, so I think it will be a while until we see profit.

Doximity (NYQ:DOCS) is another holding of mine, mainly as it benefits from high margins and a strong user base which smashed their Q4 earnings last week. Given its niche role in the industry and the growing integration of AI into healthcare platforms, this remains a company to watch.

Palantir Technologies (NSQ:PLTR) has been a hotly debated stock, but for me, its strength lies in its ability to secure high-profile government contracts worldwide. The company’s AI-driven data analytics platform is becoming an essential tool in both defence and commercial applications.

Yes, there is some sceptical noise about its ability to scale in the private sector, its recent profitability improvements suggest it is heading in the right direction. Having already gained 50% in a number of weeks, averaging on weakness I hope will provide further gains. I do admit the high valuation remains a concern, but what would Buffett do?

As Palantir continues expanding its footprint beyond government contracts, its long-term potential looks promising.

Among the most exciting companies in the portfolio is Rocket Lab USA (NAQ:RKLB) , and I was drawn to watching its presentation yesterday:

https://youtu.be/V54mWqnM8zQ?si=Ls72MbdEKv_J_YyQ

CEO Peter Beck has earned a reputation as one of the most insightful and pragmatic figures in the space industry. His vision for Rocket Lab extends beyond launch vehicles, focusing on satellite services and infrastructure, making the company a comprehensive space technology provider. He is probably the best CEO in my opinion of any the stocks I hold, down to earth (pardon the pun) and knows his beans.

One of the most interesting takeaways from Beck’s recent presentation is his view on Rocket Lab’s growth strategy. Unlike competitors like SpaceX, which prioritise heavy-lift rockets, Rocket Lab focuses on smaller payloads and rapid deployment. This strategy gives it a unique advantage in providing frequent, flexible access to space. Additionally, its vertical integration—controlling everything from design to launch—has already been achieved, meaning much of the “hard work” is done.

Looking ahead, Beck identifies defence, space, and communications as the biggest growth areas. If his predictions hold true, Rocket Lab is well-positioned to capitalise on these expanding industries. With both Rocket Lab and Filtronic (LON:FTC) making up around 20% of my portfolio each (despite taking all my money off the table), I do strongly believe these have legs to continue as they remain emerging industries. I know, for example, that countries like Mauritius with small defence/tech budgets (although now will be bolstered by the UK’s £8B plus pa), will not be looking to create their own space/satellite departments, when it will be far easier to buy off the shelf at pace.

Howard Adams

11th Feb

Hi Viz

Many thanks for your post. I see your thoughts are very much in line with my own.

I too hold Rocket Lab USA (NAQ:RKLB) but not Filtronic (LON:FTC) . Like you I see Rocket Lab USA (NAQ:RKLB) as a great space investment. I have also recently taken starter positions in Ast Spacemobile (NSQ:ASTS) and Redwire (NYQ:RDW) to expand what I term my 'AI Space' sub-portfolio.

With regard to Palantir Technologies (NSQ:PLTR) if you have not already seen it this vid from Alex of Ticker Symbol You is a very good break down of the recent results. Alex is a long term commentator on Palantir Technologies (NSQ:PLTR) and many other technical innovation stocks. He dives deep into the products as well as some of the nubers. If you do watch this vid note the commentary concerning 'the rule of 40'.

Regards

Howard

Viz

11th Feb

Thanks Howard,

Yes Ast Spacemobile (NSQ:ASTS) are a company I’m not yet invested in (lets wait until April again…) I started to look at this to see potential overlaps between ASTS and Filtronic (LON:FTC) , particularly around high-frequency satellite communications, but they are focused on different aspects of satellite broadband technology.

*edited as I could/have droned on about this for ages*

My end thoughts were if ASTS moves towards utilising higher frequencies for ground-based backhaul links, there could be an opportunity for Filtronic to supply power amplifiers or other RF components.

Complete conjecture, but note that ASTS already have a market cap of $7B vs Filtronic £200M, whilst its revenue is minuscule in comparison.

I like the rule of 40! Thanks for the video, pretty much confirms where I’m at and seeing conversion to other companies which should snowball its revenue from here.

I’m also interested seeing the Musk bid for OpenAI today and how that positions Palantir in the market space, could he potentially look at Palantir? I know he has a co-founder working with him… That said as it has been argued here before, the valuation looks fairly full. Interesting space! Although there then lies the argument of valuation of US vs UK stocks…

john2

12th Feb

Well the FT seem to have changed their mind on Palantir Technologies (NSQ:PLTR) . Today’s Lex column foresees enormous revenues.

Howard Adams

13th Feb

Hi john2

I had not seen that, thanks for the heads up.

Regards

Howard

AcornInvestor

14th Feb

Slightly off topic, apologies. Has anybody used Seeking Alpha for European stocks and would you recommend it vs Stockopedia or another similar service?

Rusty2

15th Feb

I don't think it is very good for non US markets.

BnB

15th Feb

I find the European coverage quite useful. But dwarfed by the focus on US names, esp Big Tech. Quite why some economics student thinks the world needs his take on Microsoft I can’t imagine, but many do. I would not buy a subscription just to focus on European names, however.

Howard Adams

15th Feb

Hi AcornInvestor

I do not use Seeking Alpha (SA) but see their daily headlines and have read a few articles in the distant past.

FWIW for my US investing I favour going as direct to the companies and especially the key leadership people as possible.

To that end I use YouTube a great deal to see CEO's interviews, results and earnings updates by company leaders, company podcasts about themselves, video bloggers researching companies, etc .... In support of this I also use X (Twitter) a lot and get great insights from multiple very informative contributors.

I find this 'let me see the whites of their eyes' level of research, for US investing, far more informative for my investing style than reading research from places such as SA (who so often put at directly contradictory reports on the same company).

A fundamental investing factor for me, is whether I have confidence in the character, intelligence and commitment of the leaders of a company, hence I research them quite deeply.

Regards

Howard

Rusty2

15th Feb

Read that people who write those articles get paid for them.

RJS89

16th Feb

Oscar Health (NYQ:OSCR) snapped up by quite a few famous/super investors last quarter, as revealed by their filings

tuesday will be interesting! (US market is closed on monday due to president's day)

RJS89

16th Feb

meant to add: likewise for PDD Holdings (NSQ:PDD)

seems a lot of funds are very bullish on pinduoduo & china...

Rusty2

19th Feb

Super Micro Computer (NSQ:SMCI) has been going a bit potty recently, up 3x off its recent lows. Up 18% today on no news,

joe wagner

19th Feb

I think everyone bullish on Super Micro Computer (NSQ:SMCI) because of their filing deadline approaching on the 25th. Consensus appears to be that they will be able to make that deadline and their finances are in order. As you recall, they were looking at NASDAQ delisting at the end of last year due to failing to file, and their auditor quit. But things "appear" to be turned around for SMCI and, of course, they are a profitable company in probably the hottest tech sector. Cheers!

Unlock the metrics for all these stocks and more...

Take a free trial

Facebook Twitter Youtube Instagram RSS

This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.

Unlock the metrics for all these stocks and more...

Take a free trial

US portfolio and unusual options activity

Unlock the rest of this article with a 14 day trial

About the Author

Yiannos1

190 comments

Unlock the metrics for all these stocks and more...

Unlock the metrics for all these stocks and more...